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Abstract Human prion diseases are associated with a
range of clinical presentations and are classiﬁed by both
clinicopathological syndrome and aetiology with sub-
classiﬁcation according to molecular criteria. Considerable
experimental evidence suggests that phenotypic diversity
in human prion disease relates in signiﬁcant part to the
existence of distinct human prion strains encoded by
abnormal PrP isoforms with differing physicochemical
properties. To date, however, the conformational repertoire
of pathological isoforms of wild-type human PrP and the
various forms of mutant human PrP has not been fully
deﬁned. Efforts to produce a uniﬁed international classiﬁ-
cation of human prion disease are still ongoing. The ability
of genetic background to inﬂuence prion strain selection
together with knowledge of numerous other factors that
may inﬂuence clinical and neuropathological presentation
strongly emphasises the requirement to identify distinct
human prion strains in appropriate transgenic models,
where host genetic variability and other modiﬁers of phe-
notype are removed. Deﬁning how many human prion
strains exist allied with transgenic modelling of potentially
zoonotic prion strains will inform on how many human
infections may have an animal origin. Understanding these
relationships will have direct translation to protecting
public health.
Introduction
Human prion diseases are invariably fatal conditions that
include Creutzfeldt–Jakob disease (CJD), Gerstmann–
Stra ¨ussler–Scheinker disease (GSS), fatal familial insomnia
(FFI), kuru and variant CJD (vCJD) in humans [28]. They
are associated with a range of clinical presentations and are
classiﬁed by both clinico-pathological syndrome and aeti-
ology with sub-classiﬁcation according to molecular
criteria [28, 45, 54, 90, 121, 139]. These diseases have
attracted immense research interest for many years not only
because of their unique composition and properties but also
because of their impact on public health [27, 30, 100, 129].
According to the widely accepted ‘protein-only’ hypothesis
[47], host-encoded cellular prion protein (PrP
C) is con-
verted to an alternative form designated PrP
Sc [22, 27, 30,
100, 129]. It is proposed that PrP
Sc is the infectious agent
acting to replicate itself with high ﬁdelity by recruiting
endogenous PrP
C, and that the difference between these
isoforms lies purely in the monomer conformation and its
state of aggregation [22, 27, 30, 99, 100, 102, 107, 129].
Central to understanding the molecular basis of prion
propagation remains the conundrum of prion strains—how
a protein-only infectious agent can encode information
required to specify distinct disease phenotypes—and also
the so-called species barrier effect which limits cross spe-
cies infection. While originally considered different aspects
of the prion problem, it is now clear that species barriers
and prion strains are intimately related by ‘‘conformational
selection’’ [26, 30]. Within the protein-only hypothesis of
prion propagation prion strains are thought to be encoded
by distinct pathogenic PrP conformations or assembly
states. Conformational selection proposes that although a
wide range of mammalian PrP
Sc conformations may be
possible, only a subset will be compatible with each
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prions between species (or also within species as a result of
PrP polymorphisms), therefore, relates to overlap of per-
missible PrP
Sc conformations between the structures of PrP
from the source and recipient as well as heterogeneity in
cellular mechanisms affecting prion propagation and
clearance kinetics [26, 30]. Conformational selection has
now been strongly supported by elegant studies of prions in
yeast and other fungi [14, 41, 62, 66, 106, 111, 112, 132],
and the wider relevance of prion-like mechanisms in other
proteinmisfoldingdiseasesisnowbecomingclear[30,82,85].
Understanding the molecular biology of prion disease will
illuminate processes involving protein misfolding and
aggregation and protein-based inheritance, which clearly
have far-reaching implications in pathobiology, ageing and
the evolution of cellular processes.
Aetiologies of human prion disease
Human prion diseases are biologically unique and can be
divided aetiologically into inherited, sporadic and acquired
forms [28]. Approximately 85% of human prion disease
occurssporadicallyassporadicCJDatarateof1–2casesper
million population per year across the world, with an equal
incidence in men and women [16, 27, 28, 38, 121]. Around
15% of human prion disease is associated with autosomal
dominant pathogenic mutations in PRNP, and to date, over
30 mutations have been described [27, 28, 53, 65, 80, 121].
Acquired human prion diseases forms have, until recently,
been conﬁned to rare and unusual situations. Iatrogenic CJD
has arisen as a result of transmission of CJD prions through
treatment with pituitary hormones derived from human
cadavers, implantation of dura mater grafts, corneal trans-
plantation and the use of contaminated electroencephalo-
graphic electrodes [17, 18]. The most well-known
incidences of acquired prion disease in humans resulting
from a dietary origin have been kuru that was caused by
cannibalism among the Fore linguistic group of the Eastern
Highlands in Papua New Guinea [2, 3, 35, 36, 79] and more
recently the occurrence of vCJD in the United Kingdom and
other countries due to human exposure to BSE prions
[26, 28, 120, 134]. Remarkably, kuru demonstrates that
incubation periods of infection with human prions can
exceed 50 years [35, 36].
Prion disease pathology and pathogenesis
The brains of patients with prion disease frequently show no
recognisable abnormalities on gross examination at
necropsy; however, microscopic examination typically
reveals characteristic histopathologic changes, consisting of
neuronal vacuolation and degeneration, which gives the
cerebral grey matter a microvacuolated or ‘spongiform’
appearance, and a reactive proliferation of astroglial cells
(forreviewsee[19,20]).Althoughspongiformdegeneration
is frequently detected, it is not an obligatory neuropatho-
logic feature of prion disease; the presence of astro-gliosis
and micro-gliosis, although not speciﬁc to the prion dis-
eases, is more constantly seen. The lack of a lymphocytic
inﬂammatory response is also an important characteristic.
Demonstration of abnormal PrP immunoreactivity, or more
speciﬁcally biochemical detection of PrP
Sc in brain material
byimmunoblottingtechniques(Fig. 1)isdiagnosticofprion
disease, and some forms of prion disease are characterised
by deposition of amyloid plaques composed of insoluble
aggregates of PrP [19, 20]. Amyloid plaques are a notable
Fig. 1 Immunoblot analysis of human prion disease brain. a Protein-
ase K digested brain homogenates analysed with monoclonal antibody
3F4 and enhanced chemiluminescence showing the PrP
Sc types seen
in sporadic, acquired and inherited prion disease. Types 1–3 PrP
Sc are
seen in the brain of classical forms of CJD (either sporadic or
iatrogenic CJD), while type 4 PrP
Sc is uniquely seen in vCJD brain.
Distinct PrP
Sc types are seen in cases with PRNP point mutations.
Classiﬁcation according to Hill et al. [53, 54]. b Proteinase K
digestion of brain homogenate and analysis with anti-PrP monoclonal
antibody 3F4 by enhanced chemiﬂuorescence enables calculation of
the proportions of di-, mono-, and non-glycosylated PrP. The key
shows PrP
Sc type or mutation and PRNP codon 129 genotype
(M methionine, V valine). Data points represent the mean relative
proportions of di- and mono-glycosylated PrP as percentage ± SEM.
In some cases, the error bars were smaller than the symbols used
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123featureofkuruandGSS[20,48],buttheyarelessfrequently
found in the brains of patients with sporadic CJD which
typically show a diffuse pattern of abnormal PrP deposition
[20,54] (Fig. 2). The histopathological features of vCJD are
remarkably consistent and distinguish it from other human
prion diseases with large numbers of PrP-positive amyloid
plaques that differ in morphology from the plaques seen in
kuruandGSSinthatthesurroundingtissuetakesonamicro-
vacuolated appearance, giving the plaques a ﬂorid appear-
ance [59, 134] (Fig. 2). Abundant ﬂorid plaques are
established as the neuropathological hallmark of vCJD [59]
and, to date, have only been found in association with BSE
infection in hosts homozygous for PrP with methionine at
residue 129 (in humans, primates or transgenic mice [6, 67,
119, 134]).
Distinct forms of prion disease show differences in
lymphoreticular involvement that appear to be related to
the divergent properties of distinct prion strains [1]. For
example, the tissue distribution of PrP
Sc in vCJD differs
strikingly from that in classical CJD and inherited prion
disease [51–53, 55, 57, 61, 124] with uniform and promi-
nent involvement of lymphoreticular tissues, with the
highest amounts (up to 10% of brain concentrations) in
tonsil [52, 124]. In contrast, in sporadic CJD, PrP
Sc has
only been irregularly detected by immunoblotting in non-
central nervous system tissues at very much lower levels
[46, 94]. Tonsil biopsy is used for antemortem diagnosis of
vCJD and, to date, has shown 100% sensitivity and spec-
iﬁcity [52, 121, 124], and tonsil is the tissue of choice for
prospective studies investigating the prevalence of vCJD
prion infection within the UK and other populations
[24, 42, 56]. The fact that lymphoreticular prion infection
is not a feature of iatrogenic CJD [51, 52] or kuru [15, 36]
argues that the distinct pathogenesis of vCJD relates to the
effect of prion strain rather than to a peripheral route of
infection [15, 36, 127]. The demonstration of extensive
peripheral tissue involvement in the pathogenesis of vCJD
raises concern that asymptomatically infected carriers may
be transmitting the disease to others via blood transfusion,
as now appears to have occurred [71, 93, 136], or other
iatrogenic routes including contaminated surgical and
medical instruments [4, 26, 120, 123].
Determinants of phenotypic variability in human prion
disease
The clinical presentation of human prion disease varies
enormously, and there is considerable overlap observed
between individuals with different disease aetiologies [28,
80, 120, 121] and even in family members with the same
pathogenic PRNP mutation [29, 31, 32, 65, 77, 80, 125].
Progressive dementia, cerebellar ataxia, pyramidal signs,
chorea, myoclonus, extrapyramidal features, pseudobulbar
signs, seizures and amyotrophic features can be seen in
variable combinations. Criteria used for diagnosis of human
prion disease have been deﬁned [28, 131], and deﬁnite
diagnosis of sporadic and acquired prion disease relies upon
neuropathological examination and the demonstration of
abnormal PrP deposition in the central nervous system by
eitherimmunoblottingorimmunohistochemistry[20,28,60,
128, 131]. Polymorphism at residue 129 of human PrP
[encoding either methionine (M) or valine (V)] powerfully
affectssusceptibilitytohumanpriondiseases[25,38,68,79,
Fig. 2 Distinct patterns of PrP deposition in brain in human prion
disease. The disease aetiology, PRNP codon 129 genotype of the
patient (M methionine, V valine) and the type of PrP
Sc detected in
each sample (using the London classiﬁcation of human PrP
Sc types
[54]) is designated above each brain sample. The most common
subtype of sporadic CJD (a) typically shows a diffuse, synaptic
pattern of abnormal PrP deposition, while kuru (b) shows not only
variably diffuse PrP deposition but also striking formation of PrP
plaques in various areas of the brain. These PrP plaques are
consistently distinct from those seen in vCJD (c), where PrP plaques
are often surrounded by conspicuous vacuolation, designated ‘ﬂorid
plaques’. Scale bars a, c 25 lm; b 50 lm
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12386, 135] with residue 129 acting to directly restrict the
propagation of particular prion strains through conforma-
tional selection [26, 27, 30, 119] as well as heterozygosity
conferring resistance by inhibiting homologous protein–
protein interactions [25, 30, 86]. About 38% of northern
Europeans are homozygous for the more frequent methio-
nine allele, 51% are heterozygous and 11% homozygous for
valine.HomozygosityatPRNPcodon129predisposestothe
development of sporadic and acquired CJD [25, 38, 68, 79,
86, 135] and is most strikingly observed in vCJD, where all
neuropathologically conﬁrmed cases studied so far have
been homozygous for codon 129 methionine of PRNP
[28, 81, 119, 136].
The hypothesis that alternative conformations or
assembly states of PrP provide the molecular substrate for a
signiﬁcant part of the clinicopathological heterogeneity
seen in human prion diseases and that this relates to the
existence of distinct human prion strains is supported by
considerable experimental evidence [30, 34, 90, 113] and
also by the demonstration of protein conformation-based
inheritance mechanisms of yeast prions [106, 112, 132].
Different human PrP
Sc isoforms, referred to as molecular
strain types, have been identiﬁed in the brain of patients
with phenotypically distinct forms of CJD [34, 45, 54, 88,
90, 92, 113, 122, 139] and are classiﬁed by both the frag-
ment size and ratio of the three principal PrP bands seen
after protease digestion. To date, we have characterised four
types of human PrP
Sc that can be commonly identiﬁed in
sporadic and acquired human prion diseases [27, 34, 54, 121]
(Fig. 1) although much greater heterogeneity seems likely
[121]. Sporadic and iatrogenic CJD and kuru are associated
with PrP
Sc types 1-3, while type 4 PrP
Sc is uniquely asso-
ciated with vCJD and is characterised by a fragment size
and glycoform ratio that is similar to PrP
Sc seen in BSE
and BSE when transmitted to several other species [34, 54,
122, 127]. An earlier classiﬁcation of PrP
Sc types seen in
classical CJD described only two banding patterns [88] with
PrP
Sc types 1 and 2 that we describe corresponding with the
type 1 pattern of Gambetti and colleagues and our type 3
fragment size corresponding to their type 2 pattern [87, 90].
Consensus on the nomenclature of human PrP
Sc types has
been hindered by the fact that the N-terminal conformation
of some PrP
Sc subtypes seen in sporadic CJD can be inter-
converted in vitro via changes in metal-ion occupancy
[54, 122] or solvent pH [21, 84, 138]. While it has proposed
that pH alone determines the N-terminal structure of PrP
Sc
in sporadic CJD [21, 84], this interpretation has not been
supported by other studies [69, 98, 122], and the confor-
mations of PrP
Sc types 1 and 2 that we describe in PRNP
methionine homozygous patients show critical dependence
upon the presence of copper or zinc ions under conditions,
where pH 7.4 is tightly controlled [122]. While type 4 PrP
Sc
is readily distinguished from the PrP
Sc types seen in clas-
sical CJD and kuru by a predominance of the
di-glycosylated PrP glycoform, type 4 PrP
Sc also has a
distinct proteolytic fragment size [54] although this is not
recognised by the alternative classiﬁcation which desig-
nates type 4 PrP
Sc as type 2b [87].
In addition to the distinct human PrP
Sc types associated
with sporadic and acquired prion disease, molecular strain
typing has also provided insights into the phenotypic het-
erogeneity seen inherited human prion diseases [53, 65].
Patients with inherited prion disease caused by point
mutations have glycoform ratios of PrP
Sc fragments dis-
tinct from those seen in both classical CJD and vCJD [53].
Individuals with the same PRNP mutation can also prop-
agate PrP
Sc with distinct fragment sizes [53, 96, 97].
Detection of PrP
Sc in the molecular mass range of ca.
21–30 kDa is, however, not a consistent feature, and some
cases, in particular those in which amyloid plaques are a
prominent feature, show smaller protease resistant frag-
ments of ca. 7–15 kDa [53, 65, 89, 96, 97, 110]. The
propagation of pathological isoforms of wild-type PrP may
also make a signiﬁcant contribution to phenotypic vari-
ability in inherited prion disease [23, 43, 108, 125].
Classiﬁcation of human prion disease
Efforts to produce a uniﬁed international classiﬁcation and
nomenclature of human PrP
Sc types have been complicated.
A major confounding issue in this regard has been resolving
whether relatively subtle biochemical differences in PrP
Sc
are of biological importance and accurately reﬂect the
propagation of distinct human prion strains. This is partic-
ularly true in sporadic CJD [21, 34, 44, 54, 88, 90, 91, 138],
where progress has been severely hampered by a lack of
transgenic modelling data to ﬁrmly distinguish the identity
of distinct prion strains and their deﬁning molecular and
neuropathological phenotypes. This fundamental problem
coupled with the difﬁculties and variability of the bio-
chemical methods used to distinguish PrP
Sc types [21, 54,
88, 91, 118, 122, 138] has so far precluded an internation-
ally accepted classiﬁcation system for human prion strains.
In this regard, the increasingly recognised co-occurrence of
different PrP
Sc types in the same brain [38, 49, 54, 90, 96,
98, 101, 105, 118, 125, 137] and the recognition that pro-
tease-sensitive pathological isoforms of PrP may have a
signiﬁcant role in both animal and human prion disease
[9, 39, 44, 83, 103, 104, 115–117] have further confounded
progress. Although agreement has yet to be reached on
methodological differences, nomenclature and the biologi-
cal importance of relatively subtle biochemical differences
in PrP
Sc, there is strong agreement between laboratories
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123that phenotypic diversity in human prion disease relates
in signiﬁcant part to the existence of distinct prion strains
[34, 40, 45, 50, 54, 69, 88, 90, 98, 104, 113, 139]. Despite
these advances, however, the ability of genetic background
to inﬂuence prion strain selection [6, 72–74, 81, 109],
coupled with the knowledge that route of transmission in
acquired human prion disease may dramatically inﬂuence
clinical and neuropathological presentation [17, 126, 127,
133], strongly emphasises the requirement to remove host
genetic variability and other modiﬁers of phenotype
(Table 1) by identifying distinct human prion strains in
appropriate transgenic models [5–7, 11, 13, 33, 58, 63, 64,
76, 114, 119].
Whether the diversity of phenotypes seen in human dis-
ease can be faithfully recapitulated by transgenic modelling
remains an open question. In this regard, the issue of prion
strain selection or mutation will be a major factor. As
recently hypothesised [30], prion strains may not exist as
previously thought as molecular clones with a single PrP
Sc
type(wherestrainmutationinadifferenthostwouldinvolve
generation of a distinct PrP
Sc type), but may consist of an
ensembleofmolecularspecies(containingadominantPrP
Sc
type that is preferentially propagated by its usual host) from
which a less populous subspecies may be selected by an
alternative host, resultingin a strainshift or mutation.In this
regard, different cellular populations and tissues within a
single host would provide different environments for strain
selection as recently demonstrated in vitro [70]. Given the
degree of molecular diversity observed in human prion
disease, it may be extremely difﬁcult to isolate the full
complement of human prion strains in transgenic mice
having a single genetic background.
Future perspectives
Despite major advances, the molecular basis of mammalian
prion strain diversity remains unknown. To date, the con-
formational repertoire of pathological isoforms of wild-type
human PrP and the various forms of mutant human PrP has
notbeenfullydeﬁned.Biochemicalinvestigationofdisease-
related PrP isoforms in patients allied with detailed clinical
and neuropathological analysis will continue to inform on
the diversity of phenotypes seen in human prion disease.
As it has now become clear that prion strain type, host
genetic makeup and numerous other factors may signiﬁ-
cantly inﬂuence prion disease phenotype, it is expected that
the actual number of distinct human prion strains may be far
less than the number of identiﬁed phenotypes. Detailed
transgenicmodellingwillthereforebecrucialtoestablishing
how many human prion strains exist and what the deﬁning
molecular features of PrP are for each strain. This infor-
mation allied with comprehensive transgenic modelling of
human BSE infection and other relevant, potentially
zoonotic, prion strains will inform on how many human
prion strains may have an animal origin. Understanding the
risks that existing and emerging animal prion diseases pose
will have direct translation to protecting public health.
Developmentofanaccurateclassiﬁcationforhumanprion
disease will have major implications for epidemiological
research into the causes of sporadic CJD, whose aetiology
remains obscure. While spontaneous conversion of PrP
C to
PrP
Scasararestochasticevent,orsomaticmutationofthePrP
gene, resulting in expression of a pathogenic PrP mutant are
plausible explanations for sporadic CJD [16, 27, 78, 125],
other causes for at least some cases, include environmental
exposure to human prions [37, 75, 95] or exposure to animal
prions. In this regard, the number of prion strains causing
sheep scrapie has yet to be established [8, 10, 12], and epi-
demiologicaldatacannotexcludethisasacauseofaminority
of cases. Similarities between types of sporadic CJD and
types of sheep scrapie have been reported [130]. As future
research begins to provide a more precise understanding of
the origins of human prion disease, this will facilitate
re-analysis of epidemiological data to reveal important risk
factors that might have been obscured by analysing sporadic
CJD as a single entity.
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